CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 264 enrolled
Drug / intervention
Antibacterial agent for the treatment of febrile neutropeniadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00945555
NCT00945555N/ACompleted

Multi-Center, Non-Interventional, Observational Study To Evaluate The Antibacterial Therapeutical Options In Febrile Neutropenia Patients

Pfizer·observational·Posted Jul 24, 2009·Updated Apr 5, 2017

In Brief

An observational study evaluating Antibacterial agent for the treatment of febrile neutropenia for Febrile Neutropenia. Completed, enrolled 264 participants across 5 sites.

Detailed Summary

The purpose of this study was to define and classify antibacterial agents used in Turkey for patients with febrile neutropenia.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesTurkey (Türkiye)
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 24, 2009
Enrollment StartJun 1, 2009
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.9 years ago

Interventions

Antibacterial agent for the treatment of febrile neutropeniadrug

The antibacterial agent used by the investigators for febrile neutropenia will be determined and classified in the preference order